BIOXCEL THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • February 12th, 2018 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This INDEMNIFICATION AGREEMENT (“Agreement”) is made as of , 2018 by and between BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.
BIOXCEL THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 12th, 2018 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • New York
BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell [ · ] shares (the “Firm Stock”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In addition, the Company proposes to grant to the underwriters named in Schedule I (the “Underwriters”) attached to this agreement (this “Agreement”) an option to purchase up to [·] additional shares of the Common Stock on the terms set forth in Section 2 (the “Option Stock”). The Firm Stock and the Option Stock, if purchased, are hereinafter collectively called the “Stock”. This Agreement is to confirm the agreement concerning the purchase of the Stock from the Company by the Underwriters.
EXECUTIVE AGREEMENTExecutive Agreement • February 12th, 2018 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • Connecticut
This Executive Agreement (the “Agreement”) is made and entered into effective as of September 1, 2014 (the “Effective Date”), by and between Vimal Mehta (the “Executive”) and BioXcel Corporation., a Delaware corporation (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 12th, 2018 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • Connecticut
This Executive Agreement (the “Agreement”) is made and entered into effective as of February 12, 2018 (the “Effective Date”), by and between Frank Yocca, Ph.D. (the “Executive”) and BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTRelease Agreement • February 12th, 2018 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • Connecticut
This Executive Agreement (the “Agreement”) is made and entered into effective as of , 2018 (the “Effective Date”), by and between Vimal Mehta, Ph.D. (the “Executive”) and BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”).
AMENDED & RESTATED ASSET CONTRIBUTION AGREEMENTAsset Contribution Agreement • February 12th, 2018 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • Connecticut
This Amended & Restated Asset Contribution Agreement (this “Agreement”) is entered into as of November 7, 2017 (the “Execution Date”), by and between BioXcel Corporation, a Delaware corporation located at 780 East Main Street, Branford, CT 06405 (“BioXcel”), and BioXcel Therapeutics, Inc., a Delaware corporation located at 780 East Main Street, Branford, CT 06405 (“BTI”).
STOCK PURCHASE AGREEMENTStock Purchase Agreement • February 12th, 2018 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • Connecticut
THIS AGREEMENT, dated as of , (this “Agreement”), is entered into by and between BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”), and the investors identified on Schedule 1 attached hereto (the “Investors”).
AMENDED & RESTATED SEPARATION AND SHARED SERVICES AGREEMENTAsset Contribution Agreement • February 12th, 2018 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • Connecticut
This Amended & Restated Shared Services Agreement (this “Agreement”) is entered into as of November 7, 2017 (the “Execution Date”), by and between BioXcel Corporation, a Delaware corporation located at 780 East Main Street, Branford, CT 06405 (“BioXcel”), and BioXcel Therapeutics, Inc., a Delaware corporation located at 780 East Main Street, Branford, CT 06405 (“BTI”) in order to amend and restate the obligations of each of BioXcel and BTI under that certain Separation and Shared Services Agreement (the “SSA”) entered into by BioXcel and BTI as of June 30, 2017 (the “Effective Date”). BioXcel and BTI are sometimes referred to individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO EXECUTIVE AGREEMENTExecutive Agreement • February 12th, 2018 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • Connecticut
This AMENDMENT (the “Amendment”) to the Executive Agreement (the “Agreement”), dated September 1, 2014, by and between BioXcel Corporation, a Delaware corporation (the “Company”) and Vimal Mehta (the “Executive”) is effective as of September 1, 2017 (the “Amendment Effective Date”). Capitalized terms not defined herein shall have the meanings assigned to them in the Agreement.
